Company Introduction

貝爾克斯生技股份有限公司系以開發治療腫瘤、慢性肝病之植物新藥為主要目標之研發型公司。於2016年成立的貝爾克斯，旗下所擁有的創新植物新藥BEL-X，是由工研院生醫所練兵超過15年的中草藥核心計劃團隊衍生及技轉而來，後又與農委會-農業改良場進行合作及技術移轉。同時為保護新藥之智慧財產，故獲證全球專利超過41件以上，目前已對活性部位提出專利申請，未來將持續新專利佈局和申請，以加強全球競爭力。植物新藥BEL-X目前已於2020年8月完成臨床一期試驗，結果顯示藥物具低毒性、低副作用，近期正積極規劃臨床二期試驗。
BELX Biopharmaceuticals is a research and development biotech company, aiming at developing botanical new drugs to treat tumors and chronic liver diseases. The company is playing a leadership role in Taiwan and aspires to contribute its best efforts to improve the medical and healthcare benefits for humankind.

Brief description of main products or services 

BEL-X is a botanical new drug that has entered the clinical stage, comes from a single plant of homologous origin. Based on its more than 1,000 years of experience in human use, the safety of this drug is consolidated. BEL-X's research can be dated back since 2000, a group of botanical drug experts in ITRI (Industrial Technology Research Institute) devoted themselves in a government funded project. After more than 20 years of research and development, the team has developed a safe and effective oral dosage form by using modern scientific methods to extract the active ingredients, confirming the mechanism of action, and refining the high quality manufacturing process. Currently, BEL-X has completed clinical phase I trials approved by the U.S. FDA and Taiwan TFDA, and the trial was conducted at the Clinical Trial Center of National Taiwan University Hospital and National Cheng Kung University Hospital, with satisfactory results in terms of safety and initial efficacy in subjects with various refractory solid tumor diseases.